Pfizer Inc. $PFE Position Increased by Persium Advisors LLC

by · The Cerbat Gem

Persium Advisors LLC boosted its position in Pfizer Inc. (NYSE:PFE – Free Report) by 38.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 27,123 shares of the biopharmaceutical company’s stock after buying an additional 7,589 shares during the quarter. Persium Advisors LLC’s holdings in Pfizer were worth $657,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares during the period. Northern Trust Corp lifted its stake in shares of Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after acquiring an additional 3,943,397 shares during the period. Amundi lifted its stake in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company’s stock valued at $1,045,351,000 after acquiring an additional 1,333,740 shares in the last quarter. Finally, Invesco Ltd. increased its stake in shares of Pfizer by 2.8% during the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after acquiring an additional 838,198 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. Morgan Stanley upped their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. HSBC cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, May 19th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, May 21st. Finally, Berenberg Bank dropped their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Thursday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.12.

Read Our Latest Report on PFE

Pfizer Price Performance

Shares of Pfizer stock opened at $23.91 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a fifty day simple moving average of $24.79 and a 200-day simple moving average of $24.27. The stock has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s payout ratio is currently 91.49%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).